Cyteir Therapeutics Stock Operating Margin
Cyteir Therapeutics fundamentals help investors to digest information that contributes to Cyteir Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyteir Stock. The fundamental analysis module provides a way to measure Cyteir Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyteir Therapeutics stock.
Cyteir |
Cyteir Therapeutics Company Operating Margin Analysis
Cyteir Therapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Cyteir Therapeutics has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Cyteir Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyteir Therapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyteir Therapeutics could also be used in its relative valuation, which is a method of valuing Cyteir Therapeutics by comparing valuation metrics of similar companies.Cyteir Therapeutics is currently under evaluation in operating margin category among its peers.
Cyteir Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | (20.89 M) | |||
| Shares Outstanding | 36 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 76.83 % | |||
| Number Of Shares Shorted | 319.73 K | |||
| Price To Earning | 0.36 X | |||
| Price To Book | 0.87 X | |||
| Gross Profit | (16.59 M) | |||
| EBITDA | (33.41 M) | |||
| Net Income | (33.22 M) | |||
| Cash And Equivalents | 166.4 M | |||
| Cash Per Share | 4.71 X | |||
| Total Debt | 889 K | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 19.95 X | |||
| Book Value Per Share | 3.47 X | |||
| Cash Flow From Operations | (25.79 M) | |||
| Short Ratio | 3.07 X | |||
| Earnings Per Share | (0.93) X | |||
| Price To Earnings To Growth | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 46 | |||
| Beta | 0.096 | |||
| Market Capitalization | 108.71 M | |||
| Total Asset | 153.23 M | |||
| Retained Earnings | (138.11 M) | |||
| Working Capital | 143.89 M | |||
| Current Asset | 834.8 M | |||
| Current Liabilities | 366.9 M | |||
| Net Asset | 153.23 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Cyteir Stock
If you are still planning to invest in Cyteir Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cyteir Therapeutics' history and understand the potential risks before investing.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |